REUTERS: Pfizer Inc  on Monday reported a 30per cent rise in quarterly profit, helped by demand for its branded treatments such as Ibrance, Eliquis and Xeljanz.
Pfizer, which was scheduled to report its second-quarter earnings on Tuesday, also said it would combine Upjohn, its off-patent drugs business, with Mylan NV .
Pfizer said net income rose to US$5.05 billion, or 89 cents per share, in the second quarter, from US$3.87 billion, or 65 cents per share, a year earlier.
Revenue fell 1.5per cent to US$13.26 billion.
(Reporting by Tamara Mathias in Bengaluru; Editing by Maju Samuel)